Diginex Limited announced a non‑binding memorandum of understanding to acquire The Remedy Project Limited, a specialist in data‑driven human‑rights risk assessment and worker‑centered remediation for global supply chains.
The memorandum was signed on November 21, 2025. While the financial terms of the transaction have not been disclosed, the deal will combine Diginex’s AI‑powered ESG and supply‑chain platforms with Remedy’s expertise in grievance mechanisms, forced‑labor remediation frameworks and access‑to‑remedy programs, creating an end‑to‑end solution that moves beyond risk identification to enforceable remediation for affected workers.
Diginex’s revenue grew 57% to $2.04 million in the last twelve months, yet the company continues to report negative operating and net margins, reflecting ongoing investment in technology and market expansion.
The acquisition gives Diginex the capability to meet the Corporate Sustainability Due Diligence Directive and other emerging human‑rights regulations, positioning the company to deliver a comprehensive end‑to‑end solution for responsible business conduct.
The deal expands Diginex’s advisory offerings and strengthens its competitive position in a supply‑chain sustainability software market projected to exceed $7 billion by 2029, growing at 29% CAGR from 2023.
Miles Pelham, Chairman of Diginex, said the partnership will create the industry’s most comprehensive end‑to‑end solution for responsible business conduct, while Archana Kotecha, Founder and CEO of The Remedy Project, noted the deal will scale worker‑centered approaches globally.
Diginex expects the integration to accelerate its ability to deliver AI‑powered ESG solutions and capture new revenue streams, while continuing to invest in technology and address profitability challenges.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.